home / stock / otlkw / otlkw news

OTLKW News and Press, Outlook Therapeutics Inc. Series A Warrant From 06/08/21

Stock Information
Company Name: Outlook Therapeutics Inc. Series A Warrant
Stock Symbol: OTLKW
Market: NASDAQ
Website: outlooktherapeutics.com
Menu
OTLKW OTLKW Quote OTLKW Short OTLKW News OTLKW Articles OTLKW Message Board
Get OTLKW Alerts

News, Short Squeeze, Breakout and More Instantly...
OTLKW - Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Topline readout of data from NORSE TWO targeted for calendar Q3 2021 New Biologics License Application (BLA) filing anticipated in calendar Q1 2022 ISELIN, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage...
OTLKW - Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010

Drs. Mark Humayun and Firas Rahhal, leading retinal specialists and Advisors to Outlook Therapeutics, stress clinical value of ONS-5010, if approved, over existing treatment options Registration clinical program and pre-commercialization planning for ONS-5010 remains ongoin...

OTLKW - Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update

Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021 Recently reported topline data from the NORSE THREE open-label safety study reinforce positive safety profile of ONS-5010 seen in the earlier clinical experience tri...

OTLKW - Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021

ISELIN, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, to...
OTLKW - Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg)

Positive safety profile in NORSE THREE open-label safety study reinforces previously reported safety data for ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD Topline efficacy and safety data from pi...

OTLKW - Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

MONMOUTH JUNCTION, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications...

OTLKW - Outlook Therapeutics to Participate in Cantor Fitzgerald's Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021

MONMOUTH JUNCTION, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications,...
OTLKW - Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update

Topline data from pivotal Phase 3 safety and efficacy study (NORSE TWO) on target to report in Q3 2021 Topline data from the open-label safety study (NORSE THREE) on target to report in Q2 2021 Recent funding significantly enhances financial position, extends cas...

OTLKW - Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

MONMOUTH JUNCTION, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indicati...

OTLKW - Outlook Therapeutics' Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg) Through Planned BLA Submission

Overallotment option on recent public offering partially exercised by underwriter Closed concurrent private placement for $3.0 million gross proceeds Aggregate gross proceeds of $41.6 million strengthens financial position and provides strategic optionality to maximize s...
Previous 10 Next 10